BR112019023990A2 - Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas - Google Patents

Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas Download PDF

Info

Publication number
BR112019023990A2
BR112019023990A2 BR112019023990-1A BR112019023990A BR112019023990A2 BR 112019023990 A2 BR112019023990 A2 BR 112019023990A2 BR 112019023990 A BR112019023990 A BR 112019023990A BR 112019023990 A2 BR112019023990 A2 BR 112019023990A2
Authority
BR
Brazil
Prior art keywords
carboxamides
bis
hydrofenantreno
octa
protein conjugates
Prior art date
Application number
BR112019023990-1A
Other languages
English (en)
Inventor
han Amy
J. Murphy Andrew
Olson William
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62245504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019023990(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of BR112019023990A2 publication Critical patent/BR112019023990A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated

Abstract

a presente invenção refere-se a compostos, composições e métodos para o tratamento de doenças e distúrbios associados ao receptor x do fígado, incluindo bis-octa-hidrofenantreno carboxamidas e conjugados de proteínas (por exemplo, anticorpo).
BR112019023990-1A 2017-05-18 2018-05-09 Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas BR112019023990A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508327P 2017-05-18 2017-05-18
US62/508,327 2017-05-18
PCT/US2018/031910 WO2018213082A1 (en) 2017-05-18 2018-05-09 Bis-octahydrophenanthrene carboxamides and protein conjugates thereof

Publications (1)

Publication Number Publication Date
BR112019023990A2 true BR112019023990A2 (pt) 2020-06-16

Family

ID=62245504

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023990-1A BR112019023990A2 (pt) 2017-05-18 2018-05-09 Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas

Country Status (16)

Country Link
US (2) US20180334426A1 (pt)
EP (1) EP3625209A1 (pt)
JP (2) JP2020520926A (pt)
KR (1) KR20200008579A (pt)
CN (1) CN111065622A (pt)
AU (1) AU2018269568B2 (pt)
BR (1) BR112019023990A2 (pt)
CA (1) CA3063872A1 (pt)
CL (1) CL2019003270A1 (pt)
CO (1) CO2019014286A2 (pt)
EA (1) EA201900562A1 (pt)
IL (1) IL270595B2 (pt)
MA (1) MA47392B1 (pt)
MX (1) MX2019013693A (pt)
PH (1) PH12019502576A1 (pt)
WO (1) WO2018213082A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019005330A (es) 2016-11-08 2019-09-11 Regeneron Pharma Esteroides y conjugados de proteinas de los mismos.
EP3624894A1 (en) 2017-05-18 2020-03-25 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
AU2018365946A1 (en) * 2017-11-07 2020-05-14 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
AU2019265703A1 (en) 2018-05-09 2020-11-19 Regeneron Pharmaceuticals, Inc. Anti-MSR1 antibodies and methods of use thereof
US20220080052A1 (en) 2018-11-20 2022-03-17 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
BR112021013464A2 (pt) * 2019-01-08 2021-09-21 Regeneron Pharmaceuticals, Inc. Ligantes sem traço e conjugados de proteína dos mesmos
WO2021211984A1 (en) 2020-04-16 2021-10-21 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
WO2021260232A1 (en) * 2020-06-26 2021-12-30 Synaffix B.V. Methods for the preparation of linker payload constructs
JP2023548975A (ja) 2020-11-10 2023-11-21 レジェネロン ファーマシューティカルズ， インコーポレイテッド セレン抗体複合体
CN112661783B (zh) * 2020-12-28 2022-06-07 中国林业科学研究院林产化学工业研究所 一种硅氧烷二元松香基苯并环丁烯单体及其制备方法和应用
CN115006390B (zh) * 2022-06-27 2024-04-19 国药集团动物保健股份有限公司 一种病毒减毒制剂、其制备方法以及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO2001041704A2 (en) * 1999-12-13 2001-06-14 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US6908934B2 (en) * 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
EP1766414A2 (en) * 2004-06-24 2007-03-28 Galapagos Genomics N.V. Methods and compositions to promote bone homeostasis
US7238791B1 (en) * 2005-12-16 2007-07-03 Roche Diagnostics Operations, Inc. 6-monoacetylmorphine derivatives useful in immunoassay
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
DK2167963T3 (da) 2007-05-23 2019-06-24 Ventana Med Syst Inc Polymerbærere til immunhistokemi og in situ-hybridisering
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
JP5972864B2 (ja) 2010-04-15 2016-08-17 メディミューン リミテッド ピロロベンゾジアゼピン及びそれらのコンジュゲート
WO2012005982A2 (en) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Reporter for rna polymerase ii termination
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
SG195183A1 (en) 2011-05-27 2013-12-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6170497B2 (ja) 2011-10-14 2017-07-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
AU2012322933B2 (en) 2011-10-14 2017-02-02 Medimmune Limited Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
EA026643B1 (ru) 2011-10-14 2017-04-28 Сиэтл Дженетикс, Инк. Пирролбензодиазепины и конъюгаты направленного действия
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
SI2911699T1 (en) 2012-10-23 2018-04-30 Synaffix B.V. MODIFIED AGAINST, PROTITELO-KONJUGAT AND PROCESS FOR THEIR PREPARATION
EP3057991B8 (en) * 2013-10-15 2019-09-04 The Scripps Research Institute Chimeric antigen receptor t cell switches and uses thereof
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20160324981A1 (en) * 2015-05-08 2016-11-10 The California Institute For Biomedical Research Liver x receptor agonists and uses thereof
WO2017147542A2 (en) 2016-02-26 2017-08-31 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
AU2019265703A1 (en) * 2018-05-09 2020-11-19 Regeneron Pharmaceuticals, Inc. Anti-MSR1 antibodies and methods of use thereof

Also Published As

Publication number Publication date
IL270595B1 (en) 2023-05-01
AU2018269568A1 (en) 2020-01-16
KR20200008579A (ko) 2020-01-28
MX2019013693A (es) 2020-01-27
AU2018269568B2 (en) 2022-03-24
JP2023113639A (ja) 2023-08-16
CO2019014286A2 (es) 2020-04-01
US20180334426A1 (en) 2018-11-22
IL270595B2 (en) 2023-09-01
EP3625209A1 (en) 2020-03-25
CL2019003270A1 (es) 2020-05-08
MA47392A1 (fr) 2020-10-28
MA47392B1 (fr) 2021-09-30
CN111065622A (zh) 2020-04-24
EA201900562A1 (ru) 2020-05-12
PH12019502576A1 (en) 2020-09-28
IL270595A (pt) 2019-12-31
CA3063872A1 (en) 2018-11-22
US20220112158A1 (en) 2022-04-14
JP2020520926A (ja) 2020-07-16
WO2018213082A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112017027254A2 (pt) anticorpos anti-cd123 e conjugados e derivados dos mesmos
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112013004056B8 (pt) Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
PH12016501366A1 (en) Novel anti-baff antibodies
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
BR112017012381A2 (pt) imunoterapia para doença angiogênica
PE20170768A1 (es) Anticuerpos de union a protofibrillas ab mejorados
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112017019075A2 (pt) anticorpo anti-esclerostina, fragmento de ligação ao antígeno e uso médico desses
BR112018013256A2 (pt) anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
BR112019023742A2 (pt) anticorpos anti-trkb
BR112022005787A2 (pt) Proteínas de ligação a antígeno
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]